Caliper Life Sciences, Inc. (CALP) Enters into Long-term Agreement with Trinean to Pair Complimentary Technologies

QualityStocks would like to highlight Caliper Life Sciences (NASDAQ: CALP), a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.

In the company’s news yesterday,

Caliper Life Science announced it has signed a long-term, exclusive arrangement with Trinean, a pioneer in automated micro volume spectroscopy systems. Per the agreement, Caliper will distribute Trinean’s DropSense platform under the name LabChip DS in North America.

The LabChip DS is an automated spectral analysis platform that allows users to analyze the concentration levels of nucleic acid and protein samples within minutes. The product is complementary to Caliper’s LabChip GX, which provides fluorescent, electrophoretic analysis of fragments of nucleic acids and proteins.

“Caliper is investing significant resources into developing new products, applications on our existing products, and third-party collaborations, co-marketing and distribution agreements to further augment our aggressive move into the biotherapeutics and genomics markets,” Kevin Hrusovsky, president and CEO of Caliper Life Sciences stated in the press release. “Caliper has become a vendor and partner of choice for sequencing sample preparation tools, and we are very pleased to add Trinean’s DropSense platform to the tools we offer to our customers in North America.”

The company said the idea is to use the LabChip DS for the initial concentration analysis of extracted genomic DNA, which would then be sheared using third-party equipment, then size-fractionated on a Caliper LabChip XT platform. The companies would then analyze the sheared DNA and constructed libraries would then be performed using the LabChip GXI platform to assess size, purity and amount of the DNA fragments.

“Trinean is pleased to leverage Caliper’s extensive commercial presence in the genomics and biologics markets in North America, as well as its experience in commercializing microfluidic technologies,” Marc Zabeau, CEO of Trinean stated.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.